Bristol-Myers Falls on Fear of FDA Delay on Lymphoma Therapy

(Bloomberg) -- Bristol-Myers Squibb Co. shares fell after the company said a critical inspection needed for U.S. regulators to clear a cell therapy for lymphoma hasn’t been scheduled, threatening a...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.